Painreform is trading at $0.67 (-7.17%), with no verified company-specific catalyst confirmed.
- Painreform was reported down 7.06% premarket on November 4, with no company-specific catalyst linked to the decline.
- A November 3 Dotz Nano term sheet proposes a platform sale and collaboration, but available coverage does not connect it to this move; it is non-binding and subject to further approvals.
- Biotech and major market indexes were higher, so broader market or sector weakness does not explain the drop.